Strategic Forecast for the Dry Powder Inhaler Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Dry Powder Inhaler Market Size Growth Forecast: What to Expect by 2025?
The market for dry powder inhalers has witnessed robust growth in the past few years. The market size is projected to increase from $21.25 billion in 2024 to $22.35 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.2%. The notable growth during the historic period is mainly due to factors such as resurging interest in sustainable construction materials, efforts towards cultural preservation and heritage restoration, increase in eco-friendly building practices, local procurement and community participation, and supportive regulations and building codes.

How Will the Dry Powder Inhaler Market Size Evolve and Grow by 2029?
Anticipations suggest a consistent expansion in the dry powder inhaler market in the imminent years. The market is projected to reach the value of $27.13 billion by 2029, growing annually at the rate of 5.0%. The surging forecast period growth can be linked to ongoing focus on sustainability, worldwide urbanization patterns, developments in manufacturing processes, governmental incentives and policies, along with international economic factors. The forecast period also holds major trends such as escalated research and development, resurgence of interest in traditional construction techniques, advancements in material technology, architectural and design inclination, as well as regulatory endorsements for sustainable building.

View the full report here:
https://www.thebusinessresearchcompany.com/report/dry-powder-inhaler-global-market-report

What Drivers Are Propelling the Growth of Dry Powder Inhaler Market Forward?
The continuous increase in respiratory ailments is projected to stimulate the expansion of the dry powder inhaler market. Respiratory disorders, which encompass a wide range of lung conditions, are a significant medical concern affecting the respiratory system. Dry powder inhalers prove crucial in treating these health issues such as asthma, COPD, and cystic fibrosis as they transport medicine straight to the lungs where it's most effective. This method holds a promising future compared to conventional methods of drug delivery for respiratory ailments. For example, a research report from JAMA Network Open, published in December 2023, suggested that by 2050, global COPD cases could reach nearly 600 million - a rise in prevalence of 23%. The surge of female cases is estimated at 47.1% while male cases are predicted to see a 9.4% rise. Furthermore, it is predicted that most cases will emerge in low- and middle-income regions, with the prevalence at twice the levels in high-income regions by 2050. Hence, the escalating prevalence of respiratory diseases is set to steer the growth of the dry powder inhaler market. The growth of the dry powder inhaler market is further anticipated to be fueled by the escalating levels of air pollution. Air pollution levels provide a measurement of the concentrations of multiple pollutants in the atmosphere. Such pollution contributes to respiratory problems which in turn increases the use of dry powder inhalers to deliver medication that alleviates the symptoms and manages respiratory conditions that are worsened by airborne pollutants. For instance, in 2022, the United States Environmental Protection Agency (EPA) reported the release of approximately 66 million tons of pollutants into the atmosphere in the US. Moreover, in March 2023, IQAir, an air quality technology company based in Switzerland, identified Iraq as the second most polluted country with 80.1 μg/m3 of pollutants in the air, 16 times higher than WHO's PM2.5 annual guideline for 2022. Thus, the escalating levels of air pollution are projected to stimulate the growth of the dry powder inhaler market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13430&type=smp

Which Emerging Trends Are Transforming the Dry Powder Inhaler Market in 2025?
Leading firms in the dry powder inhaler market are focusing on the creation of novel products that incorporate muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), thereby broadening their range of offerings. Muscarinic antagonists, which influence the muscarinic acetylcholine receptor, are used to manage and treat a range of conditions, including COPD and organophosphate poisoning. For example, Berry Global, an American company recognized for its development and production of diverse flexible packaging solutions, introduced its new dry powder inhaler at Pharma pack in March 2024. The inhaler aims to improve drug delivery for respiratory diseases such as COPD and asthma, providing a tailorable solution for pharmaceutical firms.

What Are the Key Segments in the Dry Powder Inhaler Market?
The dry powder inhaler market covered in this report is segmented -

1) By Product: Single-Dose Inhalers, Multi-Dose Inhalers
2) By Function: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other Applications
4) By End User: Hospitals And Clinics, Homecare Settings, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Single-Dose Inhalers: Capsule-Based Inhalers, Diskus-Based Inhalers
2) By Multi-Dose Inhalers: Blister-Based Inhalers, Rotahaler-Based Inhalers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13430&type=smp

Who Are the Key Players Shaping the Dry Powder Inhaler Market's Competitive Landscape?
Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

What Geographic Markets Are Powering Growth in the Dry Powder Inhaler Market?
North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13430

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.